The FINANCIAL -- Tokyo, Japan (September 14, 2011) - Daiichi Sankyo Company Limited
(hereafter, Daiichi Sankyo) today announced that its subsidiary, Daiichi
Sankyo Pharmaceutical (Beijing) Co., Ltd. (hereafter, Daiichi Sankyo
(Beijing)), has received approval from China's State Food and Drug
Administration (SFDA) for silodosin (Chinese product name: 优利福®), which
was developed for treatment of dysuria associated with benign prostatic
hyperplasia.
By inhibiting the alpha 1A-adrenergic receptor, which exists in the prostate, silodosin relieves the tension in the prostate, lessening pressure and reducing urethral resistance to treat dysuria associated with benign prostatic hyperplasia. Silodosin delivers faster efficacy compared with existing drugs, and can treat symptoms of urinary dysfunction, such as urinary difficulty, and other symptoms, including frequent urination and the sensation of incomplete bladder emptying.
Silodosin is a selective alpha 1A-adrenoceptor antagonist that was originally discovered by Kissei Pharmaceutical Co., Ltd. (hereafter, Kissei Pharmaceutical). It was developed by Daiichi Sankyo and Kissei Pharmaceutical in Japan and is jointly marketed under the brand name, Urief®.
Daiichi Sankyo (Beijing) has the licensing rights for development, manufacture and marketing of silodosin in China.
Daiichi Sankyo is committed to contributing to the improvement of quality of life for patients in China while increasing its presence there through the launch of silodosin and other innovative pharmaceuticals.
Related Stories
